NF-κB functions in osteoclasts

Biochemical and Biophysical Research Communications

Volumn 378, Issue 1, 2009, Pages 1-5

  Soysa, N S ^a   Alles, N ^b  

^a UNIVERSITY OF PERADENIYA   (Sri Lanka)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Canonical pathway; NF B; Non canonical pathway; Osteoclast

Indexed keywords

CYTOKINE; I KAPPA B ALPHA; I KAPPA B BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 3; PROTEIN P100; PROTEIN P105; PROTEIN P50; PROTEIN P52; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB;

CELL DIFFERENTIATION; CELL FUNCTION; KNOCKOUT MOUSE; MOLECULAR BIOLOGY; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR BINDING; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSGENIC ANIMAL; ALBERS SCHOENBERG DISEASE; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; MOUSE; MOUSE MUTANT; PATHOLOGY; REVIEW;

ANIMALS; MICE; MICE, KNOCKOUT; NF-KAPPA B; OSTEOCLASTS; OSTEOPETROSIS;

EID: 56949107998     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.10.146     Document Type: Short Survey

References (28)

1. Iotsova V., Caamano J., Loy J., Yang Y., Lewin A., and Bravo R. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat. Med. 3 (1997) 1285-1289
2. Franzoso G., Carlson L., Xing L., Poljak L., Shores E.W., Brown K.D., Leonardi A., Tran T., Boyce B.F., and Siebenlist U. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev. 11 (1997) 3482-3496
3. Hoffmann A., and Baltimore D. Circuitry of nuclear factor kappaB signaling. Immunol. Rev. 210 (2006) 171-186
4. Ducut Sigala J.L., Bottero V., Young D.B., Shevchenko A., Mercurio F., and Verma I.M. Activation of transcription factor NF-kappaB requires ELKS, an IkappaB kinase regulatory subunit. Science 304 (2004) 1963-1967
5. Solt L.A., Madge L.A., Orange J.S., and May M.J. Interleukin-1-induced NF-kappaB activation is NEMO-dependent but does not require IKKbeta. J. Biol. Chem. 282 (2007) 8724-8733
6. Lawrence T., Bebien M., Liu G.Y., Nizet V., and Karin M. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature 434 (2005) 1138-1143
7. Dejardin E. The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem. Pharmacol. 72 (2006) 1161-1179
8. Novack D.V., Yin L., Hagen-Stapleton A., Schreiber R.D., Goeddel D.V., Ross F.P., and Teitelbaum S.L. The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. J. Exp. Med. 198 (2003) 771-781
9. Ruocco M.G., Maeda S., Park J.M., Lawrence T., Hsu L.C., Cao Y., Schett G., Wagner E.F., and Karin M. I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J. Exp. Med. 201 (2005) 1677-1687
10. Jimi E., Aoki K., Saito H., D'Acquisto F., May M.J., Nakamura I., Sudo T., Kojima T., Okamoto F., Fukushima H., Okabe K., Ohya K., and Ghosh S. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in-vivo. Nat. Med. 10 (2004) 617-624
11. Soysa N.S., Alles N., Shimokawa H., Jimi E., Aoki K., and Ohya K. Inhibition of the classical NF-kB pathway prevents osteoclast bone-resorbing activity. J. Bone Miner. Metab. 27 (2009)
12. Chaisson M.L., Branstetter D.G., Derry J.M., Armstrong A.P., Tometsko M.E., Takeda K., Akira S., and Dougall W.C. Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha. J. Biol. Chem. 279 (2004) 54841-54848
13. Aya K., Alhawagri M., Hagen-Stapleton A., Kitaura H., Kanagawa O., and Novack D.V. NF-(kappa)B-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. J. Clin. Invest. 115 (2005) 1848-1854
14. Xing L., Carlson L., Story B., Tai Z., Keng P., Siebenlist U., and Boyce B.F. Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. J. Bone Miner. Res. 18 (2003) 260-269
15. Campbell I.K., Gerondakis S., O'Donnell K., and Wicks I.P. Distinct roles for the NF-kappaB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J. Clin. Invest. 105 (2000) 1799-1806
16. Xing L., Bushnell T.P., Carlson L., Tai Z., Tondravi M., Siebenlist U., Young F., and Boyce B.F. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J. Bone Miner. Res. 17 (2002) 1200-1210
17. Yamashita T., Yao Z., Li F., Zhang Q., Badell I.R., Schwarz E.M., Takeshita S., Wagner E.F., Noda M., Matsuo K., Xing L., and Boyce B.F. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J. Biol. Chem. 282 (2007) 18245-18253
18. Tucker E., O'Donnell K., Fuchsberger M., Hilton A.A., Metcalf D., Greig K., Sims N.A., Quinn J.M., Alexander W.S., Hilton D.J., Kile B.T., Tarlinton D.M., and Starr R. A novel mutation in the Nfkb2 gene generates an NF-kappa B2 "super repressor". J. Immunol. 179 (2007) 7514-7522
19. Beg A.A., Sha W.C., Bronson R.T., Ghosh S., and Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 376 (1995) 167-170
20. Rosenfeld M.E., Prichard L., Shiojiri N., and Fausto N. Prevention of hepatic apoptosis and embryonic lethality in RelA/TNFR-1 double knockout mice. Am. J. Pathol. 156 (2000) 997-1007
21. Vaira S., Alhawagri M., Anwisye I., Kitaura H., Faccio R., and Novack D.V. RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. J Clin Invest 118 (2008) 2088-2097
22. Vaira S., Johnson T., Hirbe A.C., Alhawagri M., Anwisye I., Sammut B., O'Neal J., Zou W., Weilbaecher K.N., Faccio R., and Novack D.V. RelB is the NF-kappaB subunit downstream of NIK responsible for osteoclast differentiation. Proc. Natl. Acad. Sci. USA 105 (2008) 3897-3902
23. Horwitz B.H., Scott M.L., Cherry S.R., Bronson R.T., and Baltimore D. Failure of lymphopoiesis after adoptive transfer of NF-kappaB-deficient fetal liver cells. Immunity 6 (1997) 765-772
24. Grossmann M., Metcalf D., Merryfull J., Beg A., Baltimore D., and Gerondakis S. The combined absence of the transcription factors Rel and RelA leads to multiple hemopoietic cell defects. Proc. Natl. Acad. Sci. USA 96 (1999) 11848-11853
25. Ryseck R.P., Bull P., Takamiya M., Bours V., Siebenlist U., Dobrzanski P., and Bravo R. RelB, a new Rel family transcription activator that can interact with p50-NF-kappa B. Mol. Cell. Biol. 12 (1992) 674-684
26. Weih F., Warr G., Yang H., and Bravo R. Multifocal defects in immune responses in RelB-deficient mice. J. Immunol. 158 (1997) 5211-5218
27. Weih F., Durham S.K., Barton D.S., Sha W.C., Baltimore D., and Bravo R. p50-NF-kappaB complexes partially compensate for the absence of RelB: severely increased pathology in p50(-/-)relB(-/-) double-knockout mice. J. Exp. Med. 185 (1997) 1359-1370
28. Abbadie C., Kabrun N., Bouali F., Smardova J., Stehelin D., Vandenbunder B., and Enrietto P.J. High levels of c-rel expression are associated with programmed cell death in the developing avian embryo and in bone marrow cells in-vitro. Cell 75 (1993) 899-912